iBio (NASDAQ:IBIO) Stock, Quote.Headers.trade-ideas

iBio

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Doctor,Measuring,Obese,Man,Waist,Body,Fat.,Obesity,And,Weight

Biotech

News

Health Care

Contracts

General

IBIO

iBio advances obesity treatment with IBIO-600, a long-acting anti-myostatin antibody designed for subcutaneous use, targeting reduced dosing frequency.

Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform

Come gli analisti valutano General Mills prima dei risultati del Q1

Earnings

Pre-Market Outlook

Markets

Trading Ideas

PIXY

RCAT

UXIN

AAR, ShiftPixy And 3 Stocks To Watch Heading Into Monday

Movers

iBio surged after collaborating with AstralBio Inc. to develop antibodies for obesity &amp; cardiometabolic conditions. Shares soared over 100%, hitting $2.44. Collaboration aims to target TGFb superfamily for muscle wasting &amp; obesity treatment.

Micro-Cap Stock iBio Doubles On Wednesday - Here&#39;s Why

iBio Inc

Press Releases

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

Financing

iBio Announces New Investments from Board Members and Officers

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

Abpro Hldgs

Ainos

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Elevation Oncology

Equillium

Evaxion

GlycoMimetics

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Longeveron

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Leap Therapeutics

MEI Pharma

Marker Therapeutics

MetaVia

NextCure

BiomX

SAB Biotherapeutics

Synlogic

Chardan Capital

LUCID CAPITAL MARKETS

Brookline Capital

Cantor Fitzgerald

Comments

iBio

iBio (NASDAQ:IBIO) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell